Cost-Effectiveness of Drug-Eluting Stents Including the Economic Impact of Late Stent Thrombosis

American Journal of Cardiology

Volumn 103, Issue 3, 2009, Pages 338-344

  Filion, Kristian B ^a,b,c   Roy, Arup Michael ^a   Baboushkin, Tara ^a   Rinfret, Stéphane ^d   Eisenberg, Mark J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG ELUTING STENT; ECONOMIC ASPECT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STENT THROMBOSIS;

AGED; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; SIROLIMUS; THROMBOSIS; TICLOPIDINE;

EID: 58749106789     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.086     Document Type: Article

References (31)

1. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
2. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
3. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
4. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
5. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
6. Shrive F.M., Manns B.J., Galbraith P.D., Knudtson M.L., and Ghali W.A. Economic evaluation of sirolimus-eluting stents. CMAJ 172 (2005) 345-351
7. Rinfret S., Cohen D.J., Tahami Monfared A.A., Lelorier J., Mireault J., and Schampaert E. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial. Am J Cardiovasc Drugs 6 (2006) 159-168
8. Lord S.J., Howard K., Allen F., Marinovich L., Burgess D.C., King R., and Atherton J.J. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust 183 (2005) 464-471
9. Ekman M., Sjogren I., and James S. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scand Cardiovasc J 40 (2006) 17-24
10. Kaiser C., Brunner-La Rocca H.P., Buser P.T., Bonetti P.O., Osswald S., Linka A., Bernheim A., Zutter A., Zellweger M., Grize L., and Pfisterer M.E. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
11. Bagust A., Grayson A.D., Palmer N.D., Perry R.A., and Walley T. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart 92 (2006) 68-74
12. Greenberg D., Bakhai A., and Cohen D.J. Can we afford to eliminate restenosis?. Can we afford not to?. J Am Coll Cardiol 43 (2004) 513-518
13. Cohen D.J., Bakhai A., Shi C., Githiora L., Lavelle T., Berezin R.H., Leon M.B., Moses J.W., Carrozza Jr. J.P., Zidar J.P., and Kuntz R.E. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 110 (2004) 508-514
14. Bakhai A., Stone G.W., Mahoney E., Lavelle T.A., Shi C., Berezin R.H., Lahue B.J., Clark M.A., Lacey M.J., Russell M.E., et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 253-261
15. Bowen J., Hopkins R., He Y., Blackhouse G., Lazzam C., Tu J.V., Cohen E., Tarride J.E., and Goeree R. Systematic Review and Cost-Effectiveness Analysis of Drug Eluting Stents Compared to Bare Metal Stents for Percutaneous Coronary Interventions in Ontario: Interim Report for the Ontario Ministry of Health and Long-Term Care. Report No. HTA002-0512 (2005), Ontario Ministry of Health and Long-Term Care, Hamilton, Ontario, Canada
16. Mittmann N., Brown A., Seung S.J., Coyle D., Cohen E., Brophy J., Title L., and Oh P. Economic Evaluation of Drug Eluting Stents. Report No. 53 Ottawa (2005), Canadian Coordinating Office for Health Technology Assessment, Ontario, Canada
17. Brophy J., and Erickson L. An Economic Analysis of Drug Eluting Coronary Stents: A Quebec Perspective. Report No. 04-04 (2004), Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante, Montreal, Quebec, Canada
18. Liverpool Reviews & Implementation Group. Coronary Artery Stents Rapid Systematic Review and Economic Evaluation (Addendum B). Commissioned by NHS R&D HTA Programme on Behalf of the National Institute for Clinical Excellence (2003), Liverpool Reviews & Implementation Group, Liverpool, United Kingdom
19. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., Jacobs A.K., Morrison D.A., Williams D.O., Feldman T.E., Kern M.J., O'Neill W.W., Schaff H.V., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 172-209
20. Eisenberg M.J. Drug-eluting stents: the price is not right. Circulation 114 (2006) 1745-1754
21. Ryan J., and Cohen D.J. Are drug-eluting stents cost-effective?. It depends on whom you ask. Circulation 114 (2006) 1736-1743
22. Gaziano T.A., Opie L.H., and Weinstein M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368 (2006) 679-686
23. Weinstein M.C., and Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296 (1977) 716-721
24. Cohen D.J., Taira D.A., Berezin R., Cox D.A., Morice M.C., Stone G.W., and Grines C.L. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) trial. Circulation 104 (2001) 3039-3045
25. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
26. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
27. Yock C.A., Boothroyd D.B., Owens D.K., Garber A.M., and Hlatky M.A. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med 115 (2003) 382-389
28. Nagle P.C., and Smith A.W. Review of recent US cost estimates of revascularization. Am J Manag Care 10 suppl (2004) S370-S376
29. Cowper P.A., Udayakumar K., Sketch Jr. M.H., and Peterson E.D. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol 45 (2005) 369-376
30. Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 356 (2007) 981-984
31. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997